0001209191-23-010919.txt : 20230217
0001209191-23-010919.hdr.sgml : 20230217
20230217192153
ACCESSION NUMBER: 0001209191-23-010919
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230215
FILED AS OF DATE: 20230217
DATE AS OF CHANGE: 20230217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chaubey Alka
CENTRAL INDEX KEY: 0001821605
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38613
FILM NUMBER: 23644750
MAIL ADDRESS:
STREET 1: C/O BIONANO GENOMICS, INC.
STREET 2: 9540 TOWNE CENTRE DRIVE, SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bionano Genomics, Inc.
CENTRAL INDEX KEY: 0001411690
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 261756290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 888-7600
MAIL ADDRESS:
STREET 1: 9540 TOWNE CENTRE DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Bionano Genomics, Inc
DATE OF NAME CHANGE: 20190308
FORMER COMPANY:
FORMER CONFORMED NAME: BioNano Genomics, Inc
DATE OF NAME CHANGE: 20120703
FORMER COMPANY:
FORMER CONFORMED NAME: BioNanomatrix Inc
DATE OF NAME CHANGE: 20070906
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-15
0
0001411690
Bionano Genomics, Inc.
BNGO
0001821605
Chaubey Alka
C/O BIONANO GENOMICS, INC.
9540 TOWNE CENTRE DRIVE, SUITE 100
SAN DIEGO
CA
92121
0
1
0
0
Chief Medical Officer
Common Stock
2023-02-15
4
A
0
120000
0.00
A
124794
D
Stock Option (Right to Buy)
1.63
2023-02-15
4
A
0
560000
0.00
A
2033-02-14
Common Stock
560000
560000
D
Represents restricted stock unit award granted under the Issuer's 2018 Equity Incentive Plan.
Includes 2,285 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "ESPP") on June 10, 2022 and 2,509 shares acquired under the ESPP on December 10, 2022.
The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of February 15, 2023 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.
/s/ R. Erik Holmlin, Attorney-in-Fact
2023-02-17